The earnings call reveals several negative factors: XPro's Phase II trial failure, financial losses, and reliance on future funding. Despite potential in CORDStrom's expansion and sufficient cash reserves, regulatory risks and manufacturing challenges persist. The Q&A section did not alleviate concerns, and recent stock offerings could dilute value. These outweigh the positives, suggesting a negative stock price movement.